Citigroup’s NRX Pharmaceuticals NRXP Stock Holding History

Citigroup’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-593	Closed	-$1.3K	–	5832
2024 Q4	$1.3K	Buy	+593	New	+$797	﹤0.01%	5576
2022 Q4	–	Sell	-876	Closed	-$6K	–	5897
2022 Q3	$6K	Buy	876 +778	+794%	+$5.24K	﹤0.01%	5177
2022 Q2	$1K	Sell	98 -1,423	-94%	-$18.7K	﹤0.01%	6065
2022 Q1	$37K	Buy	1,521 +1,187	+355%	+$38.6K	﹤0.01%	4863
2021 Q4	$16K	Buy	334 +286	+596%	+$20.6K	﹤0.01%	5453
2021 Q3	$4K	Buy	48 +39	+433%	+$5.07K	﹤0.01%	5610
2021 Q2	$1K	Buy	+9	New	+$2.38K	﹤0.01%	6047

Other funds holding NRXP

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OWMIAS

One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

Citigroup's NRXP Position: Q1 2025 in Review

Citigroup sold out of NRX Pharmaceuticals (NRXP) in Q1 2025, closing a stake of 593 shares — an estimated $1.3K sold.

Citigroup first reported a position in NRXP in Q2 2021 and held it in 7 quarters. The position peaked at $37K in Q1 2022. 22 funds tracked by Wall St. Rank hold NRXP as of Q1 2025.

Citigroup reported no remaining NRX Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Citigroup sold 593 NRX Pharmaceuticals shares in Q1 2025, an estimated $1.3K.
Citigroup first reported a position in NRX Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Citigroup's NRX Pharmaceuticals position peaked at $37K in Q1 2022.
22 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.